Phase 3 study of docetaxel vs vinorelbine in elderly patients with advanced non-small cell lung cancer

INTERVENTION: docetaxel 60 mg/m2 on day 1,repeated every 21 days over four cycles vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles. CONDITION: elderly patients with advanced non‐small cell lung cancer PRIMARY OUTCOME: Overall survival SECONDARY OUTCOME: safety,efficacy,QOL INCLUSION CRITERIA: Chemotherapy‐ and radiotherapy‐naïve patients with histologically or cytologically diagnosis of stage IIIB or IV NSCLC and who were over 70 years old with measurable or assessable disease were eligible for this trial.They had to have a life expectancy of at least 3 months.Additional entry criteria were as follows:(a) a performance status (PS) 0 to 2 on the Eastern Cooperative Oncology Group scale;(b) adequate function of bone marrow , kidney , liver .